Study: Semaglutide slowed progression of CKD, cut cardiovasc

Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.“These benefits signify a profound clinical impact saving kidneys, hearts and lives for patients with type 2 diabetes and chronic kidney disease,” Vlado Perkovic, MB, PS, PhD,

Related Keywords

Sydney , New South Wales , Australia , Stockholm , Sweden , Vlado Perkovic , Bymarke Neumann , Gina Brockenbrough , European Renal Association Congress , University Of New South Wales , Novo Nordisk , Evaluate Renal Function , Semaglutide Once Weekly , New England Journal ,